The opioid crisis: past, present and future policy climate in Ontario, Canada
Tóm tắt
Từ khóa
Tài liệu tham khảo
Dhalla IA, Mamdani MM, Sivilotti ML, Kopp A, Qureshi O, Juurlink DN. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ. 2009;181:891–6.
Kiepek N, Groom B, Toppozini D, Kakekagumick K, Muileboom J, Kelly L. Evaluation of an inpatient medical withdrawal program in rural Ontario: a 1-year prospective study. Can J Rural Med. 2015;20:92–7.
Lynas K. Ontario pharmacists concerned about the risks arising from approval of generic OxyContin. Can Pharm J (Ott). 2013;146:12–3.
Lynas K. Ontario police chiefs call on the federal government to keep generic OxyContin out of Canad. Canadian Pharmacist Journal. 2013;45
Standing committee on health. Office of the Speaker of the house of commons. Ottawa: Government of Canada; 2016.
College of Physicians and Surgeons. In: CPSO methadone conference; 2015.
Opioid Use and Related Adverse Events in Ontario. Ontario Drug Policy Research Network. http://odprn.ca/wp-content/uploads/2016/11/ODPRN-Opioid-Use-and-Related-Adverse-Events-Nov-2016.pdf .
Astals M, Domingo-Salvany A, Buenaventura CC, Tato J, Vazquez JM, Martin-Santos R, Torrens M. Impact of substance dependence and dual diagnosis on the quality of life of heroin users seeking treatment. Subst Use Misuse. 2008;43:612–32.
Drake RE, Brunette MF. Complications of severe mental illness related to alcohol and drug use disorders. Recent Dev Alcohol. 1998;14:285–99.
Galea S, Vlahov D. Social determinants and the health of drug users: socioeconomic status, homelessness, and incarceration. Public Health Rep. 2002;117(Suppl 1):S135–45.
Sumner A, Crichton J, Theobald S, Zulu E, Parkhurst J. What shapes research impact on policy? Understanding research uptake in sexual and reproductive health policy processes in resource poor contexts. Health Res Policy Syst. 2011;9(Suppl 1):S3.
Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abus Treat. 2005;28:321–9.
Banta-Green CJ, Maynard C, Koepsell TD, Wells EA, Donovan DM. Retention in methadone maintenance drug treatment for prescription-type opioid primary users compared to heroin users. Addiction. 2009;104:775–83.
Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis. 2012;31:207–25.
Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009:CD002209.
Herget G. Methadone and buprenorphine added to the WHO list of essential medicines. HIV AIDS Policy Law Rev. 2005;10:23–4.
Hopfer CJ, Khuri E, Crowley TJ, Hooks S. Adolescent heroin use: a review of the descriptive and treatment literature. J Subst Abus Treat. 2002;23:231–7.
Brugal MT, Domingo-Salvany A, Puig R, Barrio G, Garcia de Olalla P, de la Fuente L. Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain. Addiction. 2005;100:981–9.
Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2003:CD002209.
Gowing L, Farrell M, Bornemann R, Ali R. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2004:CD004145.
Marsch LA. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction. 1998;93:515–32.
Novick DM, Richman BL, Friedman JM, Friedman JE, Fried C, Wilson JP, Townley A, Kreek MJ. The medical status of methadone maintenance patients in treatment for 11-18 years. Drug Alcohol Depend. 1993;33:235–45.
Glanz M, Klawansky S, McAullife W, Chalmers T. Methadone vs. L-alpha-acetylmethadol (LAAM) in the treatment of opiate addiction. A meta-analysis of the randomized, controlled trials. Am J Addict. 1997;6:339–49.
Fischer B, Kurdyak P, Goldner E, Tyndall M, Rehm J. Treatment of prescription opioid disorders in Canada: looking at the 'other epidemic'? Subst Abuse Treat Prev Policy. 2016;11:12.
Eibl JK, Morin-Taus KA, Marsh DC. Too much or never enough: a response to treatment of opioid disorders in Canada: looking at the 'other epidemic'. Subst Abuse Treat Prev Policy. 2016;11:33.
Fischer B. Prescriptions, power and politics: the turbulent history of methadone maintenance in Canada. J Public Health Policy. 2000;21:187–210.
U.S. Department of Health and Human Services. https://www.surgeongeneral.gov/library/2016alcoholdrugshealth/index.html .
Chiefs of Ontario.
Patented medicine prices review board. In: Utilization of prescription opioids in Canada’s public drug plans, 2006/07 to 2012/13. Ottawa: Patented Medicine Prices Review Board; 2014.
Russell C, Firestone M, Kelly L, Mushquash C, Fischer B. Prescription opioid prescribing, use/misuse, harms and treatment among aboriginal people in Canada: a narrative review of available data and indicators. Rural Remote Health. 2016;16:3974.
Fayerman P. B.C. doctors first in Canada to face mandatory prescribing standards for opioids and other addictive drugs. In: Vancouver Sun. Vancouver; 2016. http://vancouversun.com/health/local-health/b-c-doctors-first-in-canada-to-face-mandatory-prescribing-standards-for-opioids-and-other-addictive-drugs .
Dooling K, Rachlis M. Vancouver's supervised injection facility challenges Canada's drug laws. CMAJ. 2010;182:1440–4.
Government of Canada. National Anti-drug Strategy. http://healthycanadians.gc.ca/anti-drug-antidrogue/index-eng.php .
Schneider AI, H. Social construction of target populations: implications for politics and policy. Am Polit Sci Rev. 1993;
Government of Ontario. Important Notice Regarding Change in Funding Status of Oxycodone Controlled Release Tablet. http://www.health.gov.on.ca/en/pro/programs/drugs/opdp_eo/notices/exec_office_odb_20120217.pdf .
Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med. 2012;367:187–9.
Dart RC, Severtson SG, Bucher-Bartelson B. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med. 2015;372:1573–4.
Opioid use increases after oxycodone crackdown. www.theglobeandmail.com/life/health-and-fitness/health/opioid-use-increases-after-oxycodone-crackdown/article19501813 .
Leece P, Orkin AM, Kahan M. Tamper-resistant drugs cannot solve the opioid crisis. CMAJ. 2015;187:717–8.
Dart RC, Surratt HL, Cicero TJ, Parrino MW, Severtson SG, Bucher-Bartelson B, Green JL. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med. 2015;372:241–8.
Wong A. Narcotics monitoring system (NMS) update. In: Ontario methadone prescribers conference. Toronto; 2015.
Donovan K. Doctors exploit addicts to milk OHIP: task force. In: The Toronto star. Toronto; 2007.
Fee cuts pushing Ontario doctors to close methadone clinics. http://www.theglobeandmail.com/news/national/fee-cuts-pushing-ontario-doctors-to-close-methadone-clinics/article27171502/ .
Boyle T. A methadone dispute and a system in trouble. In: Toronto Star. Toronto; 2014.
Eibl JK, Gomes T, Martins D, Camacho X, Juurlink DN, Mamdani MM, Dhalla IA, Marsh DC. Evaluating the effectiveness of first-time methadone maintenance therapy across northern, rural, and urban regions of Ontario, Canada. J Addict Med. 2015;9:440–6.
Brands JB, Brands B, Marsh DM. The expansion of methadone prescribing in Ontario, 1996–1998. Addict Res. 2000;8:485–96.
Kiepek N, Hancock L, Toppozini D, Cromarty H, Morgan A, Kelly L. Facilitating medical withdrawal from opiates in rural Ontario. Rural Remote Health. 2012;12:2193.
MMT practice task force report. http://www.health.gov.on.ca/en/common/ministry/publications/reports/methadone_taskforce/methadone_taskforce.pdf .
Astals M, Diaz L, Domingo-Salvany A, Martin-Santos R, Bulbena A, Torrens M. Impact of co-occurring psychiatric disorders on retention in a methadone maintenance program: an 18-month follow-up study. Int J Environ Res Public Health. 2009;6:2822–32.
Canadian Insitute for Health Information. Opioid-Related Harms in Canada. https://www.cihi.ca/sites/default/files/document/opioid-harms-chart-book-en.pdf .
International guidelines for estimating the costs of substance abuse. http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.1016.5362&rep=rep1&type=pdf .
Hansen RN, Oster G, Edelsberg J, Woody GE, Sullivan SD. Economic costs of nonmedical use of prescription opioids. Clin J Pain. 2011;27:194–202.
Kingston Frontenac and Addington Public Health Unit. https://public.tableau.com/profile/kflaphi#!/vizhome/OntarioOpioidSurveillanceMonitor/ACESEDVisits .
World Health Organization. Principles of Drug Dependence Treatment. http://www.who.int/substance_abuse/publications/principles_drug_dependence_treatment.pdf?ua=1 .
Keen L, Khan M, Clifford L, Harrell PT, Latimer WW. Injection and non-injection drug use and infectious disease in Baltimore City: differences by race. Addict Behav. 2014;39:1325–8.
CAMH: Do you know? Opioids. Health. CfAaM ed.; 2013.
Gomes T, Mamdani MM, Dhalla IA, Cornish S, Paterson JM, Juurlink DN. The burden of premature opioid-related mortality. Addiction. 2014;109:1482–8.
Patients First: Action Plan for Health Care. http://www.health.gov.on.ca/en/ms/ecfa/healthy_change/docs/rep_patientsfirst.pdf .
Powell B. Toronto council approves 3 supervised injection sites. Toronto Star; 2016.
City seeks federal nod to open supervised injection sites. https://www.thestar.com/news/city_hall/2016/11/30/city-seeks-federal-nod-to-open-supervised-injection-sites.html .
Health minister approves 3 supervised drug consumption sites in Montreal. http://www.cbc.ca/news/politics/safe-consumption-site-montreal-1.3969258 .
Rush. NE LHIN addiction services review. Toronto: VIRGO Planning and Evaluation Consultants; 2016.
Hausser D, Kubler D, Dubois-Arber F. Characteristics of heroin and cocaine users unknown to treatment agencies. Results from the Swiss hidden population study. Soz Praventivmed. 1999;44:222–32.
The last thing I would have expected. http://www.theglobeandmail.com/news/british-columbia/north-van-couple-lost-tofentanyl/article32933591/ .
Brend Y. North Vancouver couple's sudden death shocks family. In: CBC. Vancouver: British Columbia; 2015.
Kerr T, Stoltz JA, Tyndall M, Li K, Zhang R, Montaner J, Wood E. Impact of a medically supervised safer injection facility on community drug use patterns: a before and after study. BMJ. 2006;332:220–2.
Wood E, Tyndall MW, Montaner JS, Kerr T. Summary of findings from the evaluation of a pilot medically supervised safer injecting facility. CMAJ. 2006;175:1399–404.
Zaric GS, Bayoumi AM, Brandeau ML, Owens DK. The cost-effectiveness of counseling strategies to improve adherence to highly active antiretroviral therapy among men who have sex with men. Med Decis Mak. 2008;28:359–76.
Gartry CC, Oviedo-Joekes E, Laliberte N, Schechter MT. NAOMI: the trials and tribulations of implementing a heroin assisted treatment study in North America. Harm Reduct J. 2009;6:2.
Vacouver Coastal Health. Supervised Injection Sites. http://www.vch.ca/public-health/harm-reduction/supervised-injection-sites .
Davies H, Nutley S, Walter I. A background discussion paper for assessing the impact of social science research: conceptual, methodological and practical issues. In: ESRC Symposium on Assessing Non-Academic Impact of Research. St. Andrew University; 2005.